A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer.

Comprehensive molecular characterization and effective therapy in a rare case of metastatic renal oncocytoma ...

Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 ...

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and ...

e23291Background: Hematologic cancers (HCs) in Southeast Asia (SEA), a diverse population of over 680 million, are still understudied. Data from the 2020 Global Cancer Observatory (GCO) was used to ...

Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.

Great hope for the future: CAR T-cell and bispecific antibody therapies in multiple myeloma.Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory multiple ...

The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC. Overall survival differences did not reach statistical ...

Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors.